Oncology

Latest News

COA logo | Image Credit: © Amy Kinnamon
Community Oncology Reacts to Trump's Drug Pricing Executive Order

May 2nd 2025

An executive order signed on Tuesday, May 15, necessitated a change in plans for this panel discussion from the 2025 Community Oncology Conference, with the assembled experts, moderated by Ted Okon, MBA, executive director of the Community Oncology Alliance, speaking to how the order would reverberate across the community oncology space.

Melanoma & Skin Cancer Awareness Month | Image credit: Waseem Ali Khan - stock.adobe.com
5 Things You Should Know About Skin Cancer

May 2nd 2025

stethoscopewithcompass | Image Credit: © Talaj-stock.adobe.com
Patient Navigation Is Nonnegotiable in Cancer Care

May 1st 2025

Liver cancer - Sebastian Kaulitzki - stock.adobe.com.jpg
Elevated HLA-G Seen in HCC Driven by Viral Infections, Fatty Liver

May 1st 2025

Doctor carrying documentation for patient care | image credit: Kanisorn - stock.adobe.com.jpeg
NCODA Outlines New Patient-Centered Oncology Distribution Models

May 1st 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

AJMC EBO logo | Image credit : AJMC
February 14th 2024

How Real-World Evidence Can Spur Collaboration and Changes in Oncology

Zhaohui Su, PhD
Chandler Cortina, MD, MS, FSSO, FACS | Image Credit: Froedtert & Medical College of Wisconsin
February 9th 2024

Getting to Know Dr Chandler Cortina, Breast Surgical Oncologist

Maggie L. Shaw
Chandler Cortina, MD, MS, FSSO, FACS, is assistant professor of surgery and breast surgical oncologist at Froedtert & the Medical College of Wisconsin. His current research focuses on breast cancer risk not only in general but also among transgender and gender-diverse populations.
Miriam J. Atkins, MD, FACP, president of the Community Oncology Alliance (COA) and physician and partner of AO Multispecialty Clinic in Augusta, Georgia.
February 7th 2024

COA's Dr Miriam Atkins: PBMs, HR 5526, and Marketplace Strategy

Maggie L. Shaw Pearl Steinzor
Miriam J. Atkins, MD, FACP, president of the Community Oncology Alliance, discusses the impact of pharmacy benefit managers (PBMs) on health care costs and offers potential ways to remedy certain CMS decisions that negatively affect oncologists and their patients.
Blood sample test with positive diagnosis of thrombosis risk in a coagulation test | angellodeco - stock.adobe.com
February 2nd 2024

Risk of Venous Thromboembolism Increases After Cancer Surgery, Study Finds

Pearl Steinzor
The increased risk is likely due to the underlying cancer disease and adjuvant treatments, researchers find.
Enhertu (trastuzumab deruxtecan) product packaging | AstraZeneca photo
January 30th 2024

Priority Review Granted for Trastuzumab Deruxtecan; Would Be First Tumor-Agnostic ADC

Mary Caffrey
A tumor-agnostic approval would be a significant development in the advance of antibody-drug conjugates (ADCs), which are designed to deliver a potent, cancer-fighting payload into a tumor while sparing nearby tissues.
Dr Lucy Langer
January 28th 2024

Dr Lucy Langer: How UnitedHealthcare Is Enhancing Oncology Pathway Adherence and Promoting Equity

Hayden E. Klein
UnitedHealthcare's oncology payment mode initially involved a pay-for-performance program based on pathways adherence, and will be transitioning in 2024 to a broader system with graded quartiles to incentivize greater participation and pathway adherence.
Samyukta Mullangi, MD, MBA | Image credit: X
January 22nd 2024

Dr Samyukta Mullangi Talks Cost Reductions, Scalability of Thyme Care's Navigation Program

Hayden E. Klein
The Thyme Care virtual navigation program demonstrated a $594 reduction in total costs per member per month for navigated cancer patients compared with a control group, emphasizing the scalability of the independent virtual navigation model across various contracts, with opportunities to adapt to different populations and needs in the evolving landscape of value-based care arrangements.
ASCO GI logo | Image credit: ASCO
January 16th 2024

First-Line Tiragolumab With Atezolizumab Plus Chemo Improves PFS, OS in Patients With ESCC

Mary Caffrey
Treatment with both PD-1 and TIGIT immunotherapy alongside chemotherapy demonstrated improved progression-free (PFS) and overall survival (OS) compared with chemotherapy alone in patients with esophageal squamous cell carcinoma (ESCC).
Kirollos Hanna | Image credit: LinkedIn
January 15th 2024

Dr Kirollos Hanna Talks Chemotherapy Shortage Challenges and Solutions

Hayden E. Klein
Especially during shortages, Kirollos S. Hanna, PharmD, BCPS, BCOP, FACCC, director of pharmacy services at Minnesota Oncology, says practices should carve out areas where going to a different therapeutic approach isn't considered off-pathway.
Doctor stacking wooden blocks with health care icons | image credit: REDPIXEL - stock.adobe.com
January 14th 2024

Navigating the Biosimilar Frontier: Opportunities and Challenges in 2024

Jayne Hornung
Biosimilars offer substantial promise for a new era of accessibility and affordability for patients and the broader health care industry, but better understanding of these products from payers and providers is necessary for biosimilars to reach their full potential in the US.
Pile of dollars and stethoscope | nata777_7 - stock.adobe.com
January 11th 2024

Substantial State Variations Identified in Health Insurance Coverage at Cancer Diagnosis

Pearl Steinzor
Health insurance coverage is a strong determinant of cancer care access and survival, and the observed variations are despite a significant increase in coverage under the Affordable Care Act.
Edward Arrowsmith, MD, MPH
January 10th 2024

How Tennessee Oncology Navigates Clinical Pathway Challenges and Advancements: Dr Edward Arrowsmith

Hayden E. Klein
Edward "Ted" Arrowsmith, MD, MPH, medical director for pathways at OneOncology and managing partner at Tennessee Oncology, talks about challenges and changes in clinical pathways and the importance of keeping them updated.
Cancer awareness ribbons | SewcreamStudio - stock.adobe.com
January 8th 2024

Cancer Detection Rates Dropped Due to COVID-19 Disruptions, Study Finds

Pearl Steinzor
Cancer incidence fell by 8.7% across all cancer sites during the first year of the pandemic, according to a new study.
Dr Margaret Liang on Mitigating Financial Toxicity for Patients With Cancer
January 6th 2024

Dr Margaret Liang on Mitigating Financial Toxicity for Patients With Cancer

Pearl Steinzor Rose McNulty
Margaret Liang, MD, MSHPM, gynecologic oncologist and health services researcher and director, Gynecologic Oncology Fellowship Program, Cedars-Sinai Cancer Center, discusses financial toxicity in cancer care and how institutions can help alleviate the financial burden for patients.
Dr Amy Laughlin on At-Home Cancer Care Costs, Advancements
January 3rd 2024

Dr Amy Laughlin on At-Home Cancer Care Costs, Advancements

Brooke McCormick
Amy Laughlin, MD, MSHP, of Orlando Health commented on at-home cancer care costs and shared her predictions on how at-home cancer care will evolve.
Dr Kathi Mooney
January 3rd 2024

Dr Kathi Mooney Discusses Improving Patients' Quality of Life Through Technology

Brooke McCormick
Kathi Mooney, PhD, RN, FAAN, of the University of Utah, discussed technologies she and her team developed to help improve the quality of life of patients with cancer and their families.
Highlights From ASCO 2023
January 3rd 2024

ICYMI: Highlights From ASCO 2023

Rose McNulty
The most-read content from the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting including the latest findings in ongoing clinical trials, a panel discussion on Medicare oncology payment models, and the importance of alignment between clinicians and payers on clinical pathways.
The top 5 Institute for Value-Based Medicine content of 2023
December 27th 2023

Top 5 Content From Institute for Value-Based Medicine® Events in 2023

Laura Joszt, MA
In 2023, there were 18 oncology and 7 population health Institute for Value-Based Medicine® events cohosted with organizations such as Optum, OneOncology, Vanderbilt Ingram Cancer Center, Duke Health, Cleveland Clinic, and Memorial Sloan Kettering Cancer Center.
The Top 5 Oncology Articles of 2023
December 22nd 2023

Top 5 Most-Read Oncology Articles of 2023

Rose McNulty
Our most-read oncology content of 2023 included meeting coverage, research on an algorithm using patient-reported outcomes to predict hospital visits, and the launch of an National Comprehensive Cancer Network pilot project aiming to measure health equity.
Global-vegefox.com-stock.adobe.com
December 21st 2023

New Study Reveals Global Disparities in Access to Multiple Myeloma Cell Therapies

Giuliana Grossi
“Unfortunately, limited access to these therapies worldwide appears to be a major challenge,” the researchers wrote.
Tiago Biachi de Castria, MD, PhD, Moffitt Cancer Center
December 18th 2023

Dr Tiago Biachi Discusses Precision Medicine Advancements in Solid Tumors

Pearl Steinzor
Tiago Biachi de Castria, MD, PhD, associate member in the Department of Gastrointestinal Oncology at Moffitt Cancer Center, discusses how precision medicine tools have aided oncologists in treating patients with solid tumors, while reducing overall toxicity.
Highlights ACCC 2023 Annual Meeting and Cancer Center Business Summit
December 15th 2023

ICYMI: Highlights From ACCC Spring 2023

Rose McNulty
Our most-read coverage from the Association of Community Cancer Centers (ACCC) 2023 Annual Meeting and Cancer Center Business Summit highlighted ongoing issues in oncology policy and practice.
FDA on Paper Texture | Image credit: Araki Illustrations - stock.adobe.com
December 15th 2023

FDA Approves Belzutifan for Advanced RCC After PD-1 or PD-L1 Inhibition and a VEGF-TKI

Rose McNulty
The approval of belzutifan, an oral hypoxia-inducible factor-2 alpha inhibitor, provides a new option for patients with advanced renal cell carcinoma (RCC) following treatment with a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor and a vascular endothelial growth factor tyrosine kinase inhibitor (VEGF-TKI).
Highlights From the 2023 Community Oncology Conference
December 12th 2023

ICYMI: Highlights From the 2023 Community Oncology Conference

Rose McNulty
Our top coverage from this year’s Community Oncology Conference, hosted by the Community Oncology Alliance, included discussions around alternative payment models, shifts in the community oncology landscape in recent decades, and the need for reform in several areas.
stethoscope on charts - amazing studio - stock.adobe.com
December 8th 2023

California Aims for Equity by Redefining Cancer Care

Giuliana Grossi
Authors highlight key aspects of the California Cancer Care Equity Act, including its focus on Medi-Cal beneficiaries, the requirement for managed care plans to contract with specialized cancer centers, and the definition of complex cancers.
Quit Smoking - s@photo - stock.adobe.com
December 7th 2023

Research Reveals the Role of Structural Racism in Lung Cancer Risk

Giuliana Grossi
Spanning 22 studies, the analysis illuminated housing disparities, occupational hazards, unequal health care access, economic inequality, and discriminatory industry practices and how they collectively contribute to heightened lung cancer risks.
FDA logo on textured paper | Image credit: Araki Illustrations - stock.adobe.com
December 2nd 2023

FDA Grants Priority Review to Enfortumab Vedotin + Pembrolizumab in Metastatic Urothelial Cancer

Jordyn Sava
Positive data from the phase 3 EV-302 trial of enfortumab vedotin with pembrolizumab in locally advanced or metastatic urothelial cancer have shifted the landscape.
Hospital | Image credit: Andrii - stock.adobe.com
December 1st 2023

Gaps in Access to Cancer Care Resources May Contribute to Racial, Ethnic Disparities

Rose McNulty
Researchers found that core oncology services were less likely to be available at hospitals serving racial and ethnic minority groups compared with other hospitals in the United States.
empty prescription bottle | Image credit: Diomedes de jesus - stock.adobe.com
November 21st 2023

IQVIA Report Spotlights Shortages for Pain, Obesity, and Oncology Therapies

Skylar Jeremias
A new report from IQVIA provides an overview of current US drug shortages, shedding light on major areas of concern, such as medications to address pain, cardiovascular conditions, obesity and diabetes, and multiple forms of cancer.
Dr Alyson Moadel-Robblee on Effective Distress Screening and Support Systems for Patients With Cancer
November 17th 2023

Dr Alyson Moadel-Robblee on Effective Distress Screening and Support Systems for Patients With Cancer

Pearl Steinzor Rose McNulty
Alyson Moadel-Robblee, PhD, deputy director of community engagement and cancer health equity at Montefiore Einstein Comprehensive Cancer Center, discussed the center's evolving patient distress screening process and the Bronx Oncology Living Daily support program for patients with cancer.
<1
...
5678910111213
...
184>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo